

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 799 619 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
08.10.1997 Bulletin 1997/41

(51) Int Cl. 6: **A61K 31/505, A61K 31/445,
A61K 31/47, A61K 31/18,
A61K 31/495**

(21) Application number: **97301985.4**

(22) Date of filing: **24.03.1997**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

(30) Priority: **27.03.1996 US 14229**

(71) Applicants:
• **PFIZER INC.**
New York, N.Y. 10017 (US)
• **THE BAYLOR COLLEGE OF MEDICINE**
Houston, TX 77030-3498 (US)

(72) Inventors:
• **Thompson, Timothy C.**
Houston 77096 (US)
• **Wyllie, Michael G.**
New York, New York 10017 (US)
• **Yang, Guang**
Houston, Texas 77096 (US)

(74) Representative: **Baillie, Iain Cameron et al**
Ladas & Parry,
Althelmer Eck 2
80331 München (DE)

(54) **Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia**

(57) A method for treating or preventing a BPH in a mammal which comprises administering to said mammal an amount of a drug, comprising an α_1 -adrenore-

ceptor antagonist or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the BPH.

EP 0 799 619 A2

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to the use of α_1 -adrenoreceptor antagonists, or pharmaceutically acceptable acid addition salts, thereof for treating or preventing the formation of benign prostatic hyperplasia (BPH) in mammals. More particularly, it relates to a method for preventing the formation of, or reducing, BPH in mammals by administering to said mammals an α_1 -adrenoreceptor antagonist or pharmaceutically acceptable acid addition salt thereof.

2. General Background

Benign prostatic hyperplasia (BPH) is one of the most common, nonmalignant neoplastic processes to affect the aging man. Symptoms occur in about 50 and up to 80% of men 60 years old and older than 80 years, respectively. In the United States BPH is an important health problem resulting in an estimated 1.7 million visits to physicians offices each year.

BPH results from a progressive enlargement of the prostate, leading to urethral constriction, a disturbance in normal urinary outflow, urinary retention and associated irritative symptoms. In symptomatic BPH there appear to be two components of the urethral obstruction: a static component related to prostatic mass and a dynamic component related to the noradrenergic tone in the prostatic and urethral smooth muscle. A number of functional studies have shown that the contractile response is primarily mediated by α_1 -adrenoreceptors. Autoradiographical data suggest that these are primarily located on stromal smooth muscle.

Since approximately 50% of prostatic outflow obstruction in a patient is mediated by the sympathetic nervous system and, therefore, are potentially reversible it would be expected that urinary outflow obstruction and disease related symptoms would be relieved by α_1 -adrenoreceptor antagonists.

Early studies of phenoxybenzamine (a nonselective α_1 and α_2 adrenoreceptor antagonist) and prazosin (a selective α_1 -adrenoreceptor antagonist) were effective in the treatment of BPH with the selective α_1 agent producing fewer and more tolerable side effects than the nonselective phenoxybenzamine. In a meta-analysis of literature data the α_1 -adrenoreceptor antagonists produced a 51% decrease in BPH symptom scores, improved urinary flow rate and post-void residual volume without increasing the risk of incontinence, impotence or other adverse effects associated with surgery for BPH.

Kenny, B. et al. (α_1 -Adrenoreceptor Antagonists As Treatments For Benign Prostatic Hyperplasia, Exp. Opin. Invest. Drugs, (1995), 4(10), 915-23), incorporated herein in its entirety by reference) have discussed the use of a number of α_1 -adrenoreceptor antagonists, such as terazosin, doxazosin and its 6'- and 7'- hydroxy metabolites, indoramin and tamsulosin for the treatment of symptoms of BPH. However, they did not suggest that α_1 -adrenoreceptor antagonists could be used to prevent the formation of BPH or, if formed, treatment thereof to decrease the tumors.

Kaplan, S.A. et al, Urology, 46(4), 1995, 512-17), Kirby, R.S. (Urology, 46(2), 1995, 182-6) and Fawzy, A. et al. (The Journal of Urology, 154, 105-9 (1995)) have discussed the effect of doxazosin on the blood pressure of normotensive men who are being treated with doxazosin for mediation of the dynamic component of smooth muscle prostate outflow obstruction. However, they have not suggested that α_1 -adrenoreceptor antagonists could be used to prevent the formation of BPH or, if formed, treatment thereof to decrease the tumors.

Doxazosin, 4-amino-2-[4-(1-4-benzodioxan-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazoline and its pharmaceutically acceptable acid addition salts, are described in United States Patent Number 4,188,390 together with their use as regulators of the cardiovascular system, especially in the treatment of hypertension.

United States Patent Number 4,758,569 claims the use of doxazosin in retarding development of atherosclerosis in a mammal. The use of trimazosin or a pharmaceutically acceptable acid salt thereof, for retarding atherosclerosis is described and claimed in United States Patent Number 4,582,832.

United States Patent Numbers 4,868,216 and 4,987,152 claim the use of tamsulosin and its hydrochloride for producing α_1 -adrenoreceptor antagonistic action, or treating urinary tract dysfunction, respectively, in a host.

α_1 -Adrenoreceptor antagonists such as 2,4,6,7-tetrasubstituted quinazolines are disclosed in United States Patent Numbers 3,511,836, 4,001,237 and 4,188,390 for use as hypertensive agents. United States Patent Number 4,112,097 also claims the use of terazosin, and its tetrahydropyran-2-carbonyl homologue, for treatment of hypertension in mammals. The references do not disclose the use of those compounds for preventing the formation of, or reducing, BPH in a mammal.

Despite the many patents and studies, such as those above, relating to the use of α_1 -adrenoreceptor antagonists in the treatment of hypertension, atherosclerosis urinary tract dysfunction and smooth muscle tone in BPH there has been no report or suggestion that α_1 -adrenoreceptor antagonists, or their pharmaceutically acceptable acid addition

salts could be used to prevent the formation of, or reduce BPH in a mammal.

SUMMARY OF THE INVENTION

It has now been found that drugs consisting of α_1 -adrenoreceptor antagonists or their pharmaceutically acceptable acid addition salts, when administered to a mammal prior to the onset of BPH can prevent its formation or, after the onset of BPH, can reduce the condition. More specifically, the drugs, when administered in therapeutically effective doses, prevent formation of BPH or if BPH is already present they increase the rate of destruction (apoptosis) of the abnormal cells but do not affect normal cells. Preferably the α_1 -adrenoreceptor antagonists are selected from the group comprising alfuzosin, indoramin, terazosin, bunazosin, doxazosin and its 6'- and 7'-hydroxy metabolites, prazosin, tamsulosin, abanoquil, Recordati 15/2739 (trademark), RS 17053 (trademark), SL 89.0591 (trademark), other α_1 -adrenoreceptor antagonists mentioned by Kenny et al. (Id. at pages 917 and 919-20) and the like.

DETAILED DESCRIPTION OF THE INVENTION

This invention relates to the use of drugs comprising α_1 -adrenoreceptor antagonists and their pharmaceutically acceptable acid addition salts to prevent the formation of BPH or reduce it after formation. α_1 -Adrenoreceptor antagonists useful in the practice of the invention include alfuzosin, indoramin, terazosin, bunazosin, doxazosin, prazosin, tamsulosin, abanoquil, Recordati 15/2739 (trademark), RS 17053 (trademark), SL 89.0591 (trademark) and the like. Preferably the drugs are selected from prazosin and doxazosin and its 6'- and 7'-hydroxy metabolites, their pharmaceutically acceptable acid addition salts. Most preferred α_1 -adrenoreceptor antagonists are doxazosin and its 6'- and 7'-hydroxy metabolites.

The preferred pharmaceutically acceptable acid addition salts, of the α_1 -adrenoreceptor antagonists, for use in the practice of the invention are those prepared from mineral acids such as hydrochloric, sulfuric, nitric and phosphoric; organic acids such as sulfonic acids, e.g. benzenesulfonic (besylic), p-toluenesulfonic (PtSA, tosylic), methanesulfonic (MSA, mesylic) and trifluoromethanesulfonic (triflic); carboxylic acids e.g., acetic, propionic, benzoic, citric, tartaric, maleic, fumaric, succinic and malic. In the case of polybasic acids such as sulfuric and phosphoric the salts may be formed from any of the ionic forms thereof, e.g., in the case of phosphoric acid from its mono- di- and tribasic forms. A most preferred acid is hydrochloric.

In the prevention of the formation of BPH or reduction thereof after formation the α_1 -adrenoreceptor antagonists, or their pharmaceutically acceptable acid addition salts (hereafter the "active compounds") can be administered via oral or parenteral, including transdermal, routes. However, it is generally preferred to administer the active compounds orally. Usually, the active compounds are most desirably administered in doses ranging from about 0.01 to about 2.0 mg/kg per day. However, variations will generally be necessary depending upon the weight of the patient. The proper dose for treating or preventing the formation of benign prostatic hyperplasia (BPH) in a specific patient will easily be determined by one who is skilled in the art of prescribing and/or administering such compounds. In the case of doxazosin, for instance, the effective dosages, for treating hypertension, are from about 0.02 to about 0.60 mg/kg body weight per day with the preferred maximal oral range in man being about 0.15 to about 0.30 mg/kg body weight per day. It is to be understood that other variations may arise which depend upon the species of the patient and its individual response to a particular active compound and formulation for the time period and interval of administering the composition. It is sometimes found that dosages below the aforesaid lower levels are adequate and at other times larger dosages may be required, and administered without undesirable side effects. In the latter case it may be necessary to divide the total dose into smaller doses which can be administered throughout the day or the drug may be administered in a controlled release formulation.

For purposes of oral administration, tablets containing excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as a starch, preferably potato or tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed in soft elastic and hard-filled gelatin capsules. When aqueous suspensions and/or elixirs are desired for oral administration, the active compounds may be combined with various sweetening or flavoring agents, coloring matter and, if so desired, emulsifying and/or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof.

Although the preferred mode of administration of the active compounds is oral they may be administered parenterally as well.

For purposes of parenteral administration, solutions of the active compounds in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding water soluble acid addition salts previously enumerated. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent

rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular and subcutaneous injection purposes. In this connection, the sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art. For instance, distilled water is ordinarily used as the liquid diluent and the final preparation is passed through a suitable bacterial filter such as a sintered glass, a distomaceous-earth or an unglazed porcelain filter. Preferred filters of this type include the Berkefeld (trademark), the Chamberland (trademark) and the Asbestos Disk-Metal Seitz (trademark) filter, wherein the fluid is sucked into a sterile container with the aid of a suction pump. Needless to say, the necessary steps should be taken throughout the preparation of these injectable solutions to insure that the final products are obtained in a sterile condition.

The active compounds can also be administered transdermally. For purposes of transdermal administration the dosage form of the particular compound may include, by way of example, solutions, lotions, ointments, creams, gels, suppositories, ratelimiting sustained release formulations and devices therefor. Such dosage forms comprise the particular compound and may include ethanol, water, penetration enhancers and inert carriers such as gel-producing materials, mineral oil, emulsifying agents, benzyl alcohol and the like. Specific transdermal flux enhancing compositions are disclosed in pending U.S. patent application Ser. No. 925,641 which is assigned to the assignee of this invention, the teachings of which are incorporated herein by reference.

The effect of the drugs on apoptosis of the epithelial cells, i.e., those not involved in the portion of prostatic dysfunction, e.g., prostatic outflow obstruction, which are mediated by the sympathetic nervous system was determined by means of the mouse prostatic reconstitution (MPR) system. (See Slawin et al, *Cancer Research*, 53, 4461-5(1993)).

To determine if TGF- β 1 overexpression is involved in BPH pathogenesis we developed a model using the MPR system. Recombinant retroviruses carrying mouse TGF- β 1 cDNAs (Babe TGF- β 1 Gal and Babe TGF- β 1 Neo) or a control virus (BAG-a) were used to infect urogenital sinus (UGS) cells dissociated from 17-day old C57BL/6 mouse embryos. The UGS cells were then implanted under the renal capsules of adult male mice, where they develop into prostatic tissues under normal conditions. Relative to BAG-a controls, Babe TGF- β 1 infected MPRs contained increased numbers of focal lesions composed of benign epithelial hyperplasia as well as stromal cell hyperplasia. Immunostaining of these lesions with K-14 and tGF- β 1 antisera revealed predominantly basal epithelial cells surrounded by hyperplastic stroma with TGF- β 1 accumulation. In addition, significantly increased numbers of neuronal cells, mostly catecholaminergic, were also associated with Babe TGF- β 1 infected MPRs.

Using this model, the effects of doxazosin, an α_1 -adrenoceptor blocker, on formation of BPH lesions was evaluated. The data in Table I show that administration of doxazosin i.p. (3mg/kg b.w.) caused a significant reduction in the wet weight of MPRs infected with Babe TGF- β 1 (39.2 ± 4.8 mg, mean \pm S.E.), when compared to controls (55.6 ± 5.52 mg, $p < 0.05$) injected with sterile water only.

Table I

1	2	3	4	5
Column 1	Control*	Doxazosin*	se-c*	se-d*
Babe TGF- β 1	55.63	39.2	5.519	4.807

*values=mg; c=control; d=doxazosin

Immunohistochemistry revealed no major difference in PCNA labeling between the doxazosin-treated and untreated groups. In contrast, a significantly increased apoptotic rate (AI) in the epithelia of Babe TGF- β 1 infected MPRs was observed in the doxazosin treated group (AI=4.7) relative to the untreated group (AI=3.1, $p < 0.05$).

Table II


1	2	3	4	5
Column 1	Control*	Doxazosin*	se-c	se-d
Babe TGF- β 1	3.143	4.743	0.812	0.394

Values indicate apoptotic bodies/1000 epithelial cells. See Table I for other definitions.

Thus, it was seen that doxazosin had a pronounced effect on the formation, or destruction, of BPH. It did not have any effect on the apoptosis of normal cells. The mechanism of action for doxazosin in preventing the formation of, or destroying, BPH appears to involve induction of apoptosis within the context of prostatic development. However, the invention does not depend upon the accuracy of any theory with respect to its mechanism.

Claims

1. Use of an α_1 -adrenoreceptor antagonist, or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the BPH for the preparation of a medicament for treating or preventing BPH in a mammal.
2. The use according to claim 1, wherein said α_1 -adrenoreceptor antagonist is selected from the group comprising alfuzosin, indoramin, terazosin, bunazosin, doxazosin and its 6'- and 7'- hydroxy metabolites, prazosin, tamsulosin, abanoquil, Recordati 15/2739 (trademark), RS 17053 (trademark) and SL 89.0591 (trademark).
3. The use according to claim 2, wherein the α_1 -adrenoreceptor antagonist is selected from prazosin, doxazosin and its 6'- and 7'- hydroxy metabolites and pharmaceutically acceptable acid addition salts thereof.
4. The use according to claim 3, wherein the α_1 -adrenoreceptor antagonist is doxazosin and its 6'- and 7'-hydroxy metabolites.
5. The use according to claim 4, wherein the α_1 -adrenoreceptor antagonist is the 6'- hydroxy metabolite of doxazosin.
6. The use according to claim 4, wherein the α_1 -adrenoreceptor antagonist is the 7'- hydroxy metabolite of doxazosin.
7. The use according to claim 1, 2, 3, 4, 5 or 6, wherein said medicament is formulated to be administered orally.
8. The use according to claim 1, 2, 3, 4, 5 or 6, wherein said medicament is formulated to be administered intraperitoneally.
9. The use according to claim 1, 2, 3, 4, 5 or 6, wherein said medicament is formulated to be administered transdermally.
10. The use according to claim 1, 2, 3, 4, 5 or 6, wherein said medicament is formulated to be administered parenterally.
11. A composition for treating or preventing a BPH in a mammal which comprises an amount of a drug comprising an α_1 -adrenoreceptor antagonist, or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing BPH for daily administration.
12. The composition according to claim 11, wherein said α_1 -adrenoreceptor antagonist is selected from the group comprising alfuzosin, indoramin, terazosin, bunazosin, doxazosin and its 6'- and 7'- hydroxy metabolites, prazosin, tamsulosin, abanoquil, Recordati 15/2739 (trademark), RS 17053 (trademark) and SL 89.0591 (trademark).
13. The composition according to claim 12, wherein the α_1 -adrenoreceptor antagonist is selected from doxazosin and its 6'- and 7'- hydroxy metabolites and prazosin.
14. The composition according to claim 13, wherein the α_1 -adrenoreceptor antagonist is selected from doxazosin and its 6'- and 7'- hydroxy metabolites.
15. The composition according to claim 14, wherein the α_1 -adrenoreceptor antagonist is the 6'- hydroxy metabolite of doxazosin.
16. The composition according to claim 14, wherein the α_1 -adrenoreceptor antagonist is the 7'- hydroxy metabolite of doxazosin.
17. The composition of claim 11, 12, 13, 14, 15 or 16, consisting of a controlled release formulation comprising an effective daily dose of the drug.
18. A composition according to claim 11, 12, 13, 14, 15 or 16, in the form of a transdermal patch.



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 799 619 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
12.11.1997 Bulletin 1997/46

(51) Int Cl.⁶: **A61K 31/505**, A61K 31/445,
A61K 31/47, A61K 31/18,
A61K 31/495

(43) Date of publication A2:
08.10.1997 Bulletin 1997/41

(21) Application number: **97301985.4**

(22) Date of filing: **24.03.1997**

(84) Designated Contracting States:
**AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL
PT SE**

(30) Priority: **27.03.1996 US 14229**

(71) Applicants:
• **PFIZER INC.**
New York, N.Y. 10017 (US)
• **THE BAYLOR COLLEGE OF MEDICINE**
Houston, TX 77030-3498 (US)

(72) Inventors:
• **Thompson, Timothy C.**
Houston 77096 (US)
• **Wyllie, Michael G.**
New York, New York 10017 (US)
• **Yang, Guang**
Houston, Texas 77096 (US)

(74) Representative: **Ballile, Iain Cameron et al**
Ladas & Parry,
Alzheimer Eck 2
80331 München (DE)

(54) **Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia**

(57) A method for treating or preventing a BPH in a mammal which comprises administering to said mammal an amount of a drug, comprising an α_1 -adrenore-

ceptor antagonist or pharmaceutically acceptable acid addition salt thereof, effective for treating or preventing the BPH.

EP 0 799 619 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 97 30 1985

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
P,X	WO 96 22992 A (ABBOTT LAB) 1 August 1996 * p.3, 1.6-19; p.43-54; claims 13 and 14 *	1-18	A61K31/505 A61K31/445 A61K31/47
X	WO 95 28932 A (FLORA INC) 2 November 1995 * Table 1; claims 1-23 *	1-18	A61K31/18 A61K31/495
X	WO 95 28157 A (SYNAPTIC PHARMA CORP ; GLUCHOWSKI CHARLES (US); FORRAY CARLOS C (US) 26 October 1995 * p.3, 1.36-37; claim 1, Table 4 *	1-18	
X	US 5 436 264 A (PFISTER JURG R ET AL) 25 July 1995 * col. 1, 1.33-43; claims 11-16 *	1-18	
X	WO 95 04072 A (CHIRON CORP ; SPELLMEYER DAVID C (US); MOOS WALTER H (US); MARTIN E) 9 February 1995 * p.7, 1.14-p.8,17; claims 1 and 15 *	1-18	
X	INT. J. OF CLIN. PHARM. THER. AND TOXICOLOGY , vol. 27, no. 8, 1989, pages 392-7, XP000655044 LEPOR ET AL: "The safety and efficacy of terazosin..." * abstract; p.395-96, Discussion *	1-18	TECHNICAL FIELDS SEARCHED (Int.Cl.6) A61K
X	EP 0 673 650 A (SYNTHELABO) 27 September 1995 * p.2, 1.4-5; claims 1-9 *	1-18	
X	EP 0 582 502 A (SYNTHELABO) 9 February 1994 * col.1, 1.23; claims 1-5 *	1-18	
X	EP 0 564 093 A (PFIZER) 6 October 1993 * claims 1-5 *	11-18	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 12 September 1997	Examiner Uiber, P
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : technological background O : non-written disclosure P : intermediate document & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EP 0 799 619 A3 (P40001)